 | • レポートコード：MRC2203A088 • 出版社/出版日：Mordor Intelligence / 2022年1月 • レポート形態：英文、PDF、111ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Site Licence | ￥962,000 (USD6,500) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本市場調査レポートでは、世界の犬関節炎市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、薬剤クラス別（抗炎症薬、栄養補助食品、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米）分析、競争状況、市場機会・将来傾向など、以下の構成でまとめました。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の犬関節炎市場規模：薬剤クラス別（抗炎症薬、栄養補助食品、その他） ・世界の犬関節炎市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争状況（Nutri-Vet, LLC、Boehringer Ingelheim、Liquid Health Inc.、…） ・市場機会・将来傾向 |
The prevalence of obesity among the pet population is increasing all over the globe. Owing to the fact that excess fat and body weight increases the load on joints, obesity is directly associated with osteoarthritis in dogs, which results in difficulty of movement. According to the results of the 2017 Pet Obesity Survey conducted by the Association for Pet Obesity Prevention (APOP), 56% of dogs were identified as overweight (body condition score (BCS) 6-7) or obese (BCS 8-9), while in 2016, APOP classified 54% of dogs as overweight or obese, in the United States. The American Animal Hospital Association (AAHA) estimated 40-50% of dogs to be overweight, and 25% of dogs to be obese, in 2017. According to data published in a journal, namely, Frontiers in Veterinary Science, in 2017, 40.9% of dogs have been identified to be obese (BCS 7/9-9/9) in the obesogenic areas in Spain.
Thus, the rise in the prevalence of canine obesity has made it the most common nutritional health problem in dogs, which results in osteoarthritis, hence driving the growth of the market studied.
Key Market Trends
Anti-Inflammatory Drugs to Witness Healthy Growth Over the Forecast Period
Anti-inflammatory medications, known as nonsteroidal anti-inflammatory drugs (NSAIDs), are frequently used to manage your dog’s condition and can offer a dramatic improvement in mobility and quality of life. NSAIDs reduce the production of prostaglandins which drive inflammation associated with arthritis. They do this by blocking an enzyme called cyclooxygenase.
However, there are at least two forms of this enzyme cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), and it is cox-2 which is believed to be the chief culprit for creating these inflammatory prostaglandins. COX-1 is recognised to produce prostaglandins that are beneficial within the body as they protect the stomach lining, aid in kidney function and help in clotting. Developments in NSAIDs in the last decade have created more COX-2 selective drugs which should reduce the side effects seen, however adverse reactions can still happen.
International companies such as Elanco provide FDA approved NSAIDs for treating arthritis. Galliprant (by Elanco) is a first-of-its-kind, targeted NSAID that treats canine osteoarthritis pain and inflammation. It’s a prescription-only, chewable osteoarthritis medicine for dogs that’s safe to use daily.
Therefore, owing to the effectiveness of anti-inflammatory drugs in treatment of canine arthritis and the availability of various brands from major companies, the segment is expected to witness healthy growth over the forecast period.
United States Holds a Significant Share
The United States is expected to retain a large share of the canine arthritis market, over the forecast period, owing to increasing companion animal adoption, the rising prevalence of canine arthritis, and an increase in per capita animal healthcare expenditure.
As per the results of the American Pet Products Association’s 2017-2018 National Pet Owners Survey, 60.2 million households in the United States have pet dogs. Added to that, according to a report published by Stephanie Clark, Department of General Internal Medicine, Murray State University, in 2015, among all domestic and pet animal species, dogs suffer from osteoarthritis more often as a result of excessive running, exercise, injury, and genetic predisposition. The report states that one-fourth of the 77.2 million pet dogs in the United States have been diagnosed with arthritis. Also, as per data published by the American Pet Products Association, in 2018, the total pet healthcare expenditure has been estimated to be USD 72.13 Billion, while that in 2017 was found to be USD 69.51 Billion. Owing to the aforementioned statements, the United States is believed to hold a significant share of the market studied.
Competitive Landscape
Veterinary healthcare has rapidly evolved over the last few years, where technology concerning biotech, genomics, artificial intelligence, cloud computing, and big data has grown massively, bringing competition among large animal health companies and collaborations with technologically advanced start-ups. Also, the industry observed significant mergers and acquisitions in recent years, such as between Boehringer Ingelheim Animal Health and Merial. Such strategic steps taken by the key players are making the key companies more competitive in the market.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 High Prevalence of Canine Obesity and Motion Injuries
4.2.2 Increase in Awareness regarding Canine Health
4.3 Market Restraints
4.3.1 High Cost of Treatment
4.3.2 Side Effects Associated with Treatment Errors
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Drug Class
5.1.1 Anti-Inflammatory
5.1.2 Nutraceutical Supplement
5.1.3 Others
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle-East and Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle-East and Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 COMPANY PROFILES
6.1.1 Nutri-Vet, LLC
6.1.2 Boehringer Ingelheim
6.1.3 Liquid Health Inc.
6.1.4 American Regent, Inc.
6.1.5 Matsun Nutrition
6.1.6 Synflex America Inc.
6.1.7 Thorne Research Inc.
6.1.8 Vetalogica
6.1.9 Elanco
7 MARKET OPPORTUNITIES AND FUTURE TRENDS